Gaudium IVF

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE0P8B01020
  • NSEID: GAUDIUMIVF
  • BSEID: 544709
INR
95.84
0.19 (0.2%)
BSENSE

Apr 13

BSE+NSE Vol: 54.18 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

54.18 lacs (39.46%) Volume

Shareholding (Feb 2026)

FII

9.24%

Held by 8 FIIs

DII

5.05%

Held by 2 DIIs

Promoter

71.29%

Why is Gaudium IVF and Women Health Ltd falling/rising?

13-Apr-2026

As of 12-Apr, Gaudium IVF and Women Health Ltd's stock price is rising to 95.65, reflecting a 7.62% increase. This growth is driven by strong performance relative to the Sensex, increased investor participation, and positive technical indicators.

As of 12-Apr, Gaudium IVF and Women Health Ltd's stock price is rising, currently at 95.65, reflecting a change of 6.77 or 7.62% increase. This upward movement can be attributed to several factors. Over the past week, the stock has gained 23.71%, significantly outperforming the Sensex, which only increased by 5.77% during the same period. Additionally, in the last three days, the stock has consistently risen, accumulating a total return of 21.74%. <BR><BR>Today, the stock reached an intraday high of Rs 99.5, representing an increase of 11.95%. It is also close to its 52-week high, being just 4.34% away from Rs 99.8. The stock's performance today has outpaced its sector by 7.05%, indicating strong relative strength. <BR><BR>Moreover, there has been a notable increase in investor participation, with delivery volume on April 9 rising by 515.13% compared to the 5-day average. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator. Overall, these factors contribute to the rising trend in Gaudium IVF and Women Health Ltd's stock price.

View full answer

Which are the latest news on Gaudium IVF?

13-Apr-2026
No latest news for Gaudium IVF found.

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 715 Cr (Micro Cap)

stock-summary
P/E

37.00

stock-summary
Industry P/E

57

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.27

stock-summary
Return on Equity

36.63%

stock-summary
Price to Book

15.32

Revenue and Profits:
Net Sales:
25 Cr
(Quarterly Results - Dec 2025)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Icon
Company does not have enough history
Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

10-Apr-2026 | Source : BSE

Compliance Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations 2018

Gaudium IVF And Women Health Limited Has Updated The Exchange On The Query Received From BSE Limited Vide Its Email Dated April 07 2026 Seeking Additional Details For Corporate Announcement Dated April 06 2026 Filed Under Regulation 30 Of SEBI (LODR) Regu

07-Apr-2026 | Source : BSE

Gaudium IVF and Women Health Limited has updated the Exchange on the query received from BSE Limited vide its email dated April 07 2026 seeking additional details for Corporate Announcement dated April 06 2026 filed under Regulation 30 of SEBI (LODR) Regulations 2015

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)

06-Apr-2026 | Source : BSE

Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations)

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
19.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
24.53%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.35%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
37
Industry P/E
57
Price to Book Value
15.35
EV to EBIT
27.46
EV to EBITDA
25.48
EV to Capital Employed
12.31
EV to Sales
12.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
44.85%
ROE (Latest)
41.01%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Bullish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Feb 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 8 FIIs (9.24%)

Promoter with highest holding

Manika Khanna (70.73%)

Highest Public shareholder

Meru Investment Fund Pcc-cell 1 (2.96%)

Individual Investors Holdings

13.52%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -38.17% vs 64.52% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -64.78% vs 169.55% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.19",
          "val2": "22.95",
          "chgp": "-38.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.83",
          "val2": "13.28",
          "chgp": "-56.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.12",
          "val2": "0.51",
          "chgp": "119.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.18",
          "val2": "9.03",
          "chgp": "-64.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.09%",
          "val2": "57.86%",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Gaudium IVF"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Gaudium IVF"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 12.98% vs 18.65% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 11.96% vs 25.49% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "59.00",
          "val2": "52.22",
          "chgp": "12.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.86",
          "val2": "25.07",
          "chgp": "11.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.39",
          "val2": "0.54",
          "chgp": "157.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "18.63",
          "val2": "16.64",
          "chgp": "11.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "47.22%",
          "val2": "48.01%",
          "chgp": "-0.79%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
14.19
22.95
-38.17%
Operating Profit (PBDIT) excl Other Income
5.83
13.28
-56.10%
Interest
1.12
0.51
119.61%
Exceptional Items
0.00
0.00
Standalone Net Profit
3.18
9.03
-64.78%
Operating Profit Margin (Excl OI)
41.09%
57.86%
-16.77%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -38.17% vs 64.52% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -64.78% vs 169.55% in Sep 2025

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
59.00
52.22
12.98%
Operating Profit (PBDIT) excl Other Income
27.86
25.07
11.13%
Interest
1.39
0.54
157.41%
Exceptional Items
0.00
0.00
Standalone Net Profit
18.63
16.64
11.96%
Operating Profit Margin (Excl OI)
47.22%
48.01%
-0.79%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 12.98% vs 18.65% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 11.96% vs 25.49% in Mar 2024

stock-summaryCompany CV
About Gaudium IVF and Women Health Ltd stock-summary
stock-summary
Gaudium IVF and Women Health Ltd
Micro Cap
Healthcare Services
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available